The trademark application e therapeutics was filed by E-THERAPEUTICS PLC, a corporation established under the laws of the United Kingdom of Great Britain and Northern Ireland (the "Applicant"). The application was published for oppositions on December 8, 2022, and it was registered by office on March 17, 2023 without any oppositions.
The application was filed in English (German was selected as the second language).
Partial Surrender of the trademark registration was recorded on October 2, 2024.
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical and medical preparations
Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression
RNAi-based medicines and pharmaceuticals
Short interfering RNA (siRNA) medicines and pharmaceuticals
Nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression
Pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation
None of the aforementioned goods for, or related to, T-cells or T-cell receptors.
The mark was filed in class 9 with following description of goods:
Computer software for use in the field of pharmaceuticals, medicines and drug discovery
Artificial intelligence and machine learning software for use in the field of pharmaceuticals, medicines and drug discovery
Electronic databases for use in the field of pharmaceuticals, medicines and drug discovery
Computer platform software platforms for use in the field of pharmaceuticals, medicines and drug discovery
Computer software platforms for use in the field of pharmaceuticals, medicines and drug discovery
None of the aforementioned goods for, or related to, T-cells or T-cell receptors.
The mark was filed in class 40 with following description of goods:
Custom manufacture of pharmaceutical and medical preparations
Custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression
Custom manufacture of RNAi-based pharmaceuticals and medicines
Custom manufacture of short interfering RNA (siRNA) medicines
Custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression
Custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation
Provision of information, advice and consultancy services relating to all of the aforesaid
None of the aforementioned services for, or related to, T-cells or T-cell receptors.
The mark was filed in class 42 with following description of goods:
Pharmaceutical research and development services
Scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression
Scientific, pharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines
Scientific, pharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression
Scientific, pharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking gene expression, nucleic acidbased drugs (NABDs) for blocking, silencing or inhibiting gene expression, and, pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation
Drug discovery services
Drug discovery services relating to RNAi-based pharmaceuticals and medicines
Drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression
Drug discovery services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation
Genetic research
Scientific and technical data analysis in relation to pharmaceuticals and medicines
Scientific and technical data analysis in relation to RNAibased medicines
Scientific and technical data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression
Scientific and technical data analysis in relation to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation
Design, development, creation and maintenance of computer platforms and computer software for use in the field of pharmaceuticals, medicines and drug discovery
Platform as a Service (PaaS) services relating to the use of artificial intelligence and machine learning software and databases in the field of pharmaceuticals, medicines and drug discovery
Platform as a Service (PaaS) services relating to the use of artificial intelligence and machine learning software and databases in relation to RNAi-based medicines and pharmaceuticals, short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation
Design of computer-simulated models for use in the field of pharmaceuticals, medicines and drug discovery
Providing non-downloadable computer software
Providing non-downloadable computer software for use in the field of pharmaceuticals, medicines and drug discovery
Software as a Service (SaaS) services relating to the use of artificial intelligence and machine learning software and databases in the field of pharmaceuticals, medicines and drug discovery
Software as a Service (SaaS) services relating to the use of artificial intelligence and machine learning in relation to RNAi-based medicines and pharmaceuticals, nucleic acidbased drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation
Provision of information, advice and consultancy services relating to all of the aforesaid
None of the aforementioned services for, or related to, T-cells or T-cell receptors.